Renovacor, Inc. operates as a clinical stage gene therapy company. The company is headquartered in Cambridge, Massachusetts and currently employs 19 full-time employees. The company went IPO on 2020-04-24. The firm is engaged in developing a pipeline of adeno-associated virus (AAV)-based gene therapies for Bcl2-associated athanogene 3 (BAG3) gene mutation-associated diseases in areas of unmet medical need. The firm's therapeutic focuses on cardiovascular disease, with a lead program in BAG3 mutation-associated dilated cardiomyopathy. Its lead product candidate, REN-001, is an AAV9-based gene therapy designed to treat BAG3-associated dilated cardiomyopathy (DCM). The firm is also conducting preclinical studies exploring the ability of a BAG3 gene therapy to treat patients suffering from DCM caused by BAG3 haploinsufficiency. The Company’s preclinical strategy is to advance earlier stage research programs of its BAG3 gene therapy. Its research and discovery programs include BAG3- mediated diseases associated with the cardiovascular system and the central nervous system.

Industry: Biological Products, (No Diagnostic Substances) Peers: Achieve Life Sciences Inc Dominari Holdings Inc Tectonic Therapeutic Inc SAB Biotherapeutics Inc BioCardia Inc Lisata Therapeutics Inc Corvus Pharmaceuticals Inc Moleculin Biotech Inc T2 Biosystems, Inc.